CLAIMS

[Claim 1] An antihypertensive pharmaceutical composition, comprising:
Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an angiotensin II receptor blocker; and
Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as a calcium channel blocker.

[Claim 2] The antihypertensive pharmaceutical composition ~~of~~ according to claim 1, wherein ~~a pharmaceutically acceptable salt of Fimasartan~~ the angiotensin II receptor blocker is a Fimasartan potassium salt, hydrochloride, calcium salt, sulfate, adipate, camsylate or besylate.

[Claim 3] The antihypertensive pharmaceutical composition ~~of~~ according to claim 2, wherein ~~a pharmaceutically acceptable salt of Fimasartan~~ the angiotensin II receptor blocker is a Fimasartan potassium salt.

[Claim 4] The antihypertensive pharmaceutical composition ~~of~~ according to claim 1, wherein ~~a hydrate of pharmaceutically acceptable salt of Fimasartan~~ the angiotensin II receptor blocker is a Fimasartan potassium trihydrate.

[Claim 5] The antihypertensive pharmaceutical composition ~~of~~ according to claim 1, wherein ~~a pharmaceutically acceptable salt of Amlodipine~~ the calcium channel blocker is an Amlodipine besylate, sulfate, camsylate, hydrochloride, potassium salt, calcium salt or adipate.

[Claim 6] The antihypertensive pharmaceutical composition ~~of~~ according to claim 5, wherein ~~a pharmaceutically acceptable salt of Amlodipine~~ the calcium channel blocker is an Amlodipine besylate.

[Claim 7] ~~The antihypertensive pharmaceutical composition of claim 1, wherein the amount of Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof is in the range of 0.5 to 240 mg, and the amount of Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof is in the range of 0.1 to 20 mg.~~
The antihypertensive pharmaceutical composition according to any one of claims 1 to 3, wherein the content of the angiotensin II receptor blocker is in the range of 0.5 to 240 mg, and the content of the calcium channel blocker is in the range of 0.1 to 20 mg.

[Claim 8] The antihypertensive pharmaceutical composition ~~of~~ according to claim 7,

wherein the ~~amount of Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof~~ content of the angiotensin II receptor blocker is in the range of 50 to 180 mg.

[Claim 9] The antihypertensive pharmaceutical composition ~~of~~ according to claim 8, wherein the ~~amount of Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof~~ content of the angiotensin II receptor blocker is in the range of 60 to 120 mg.

[Claim 10] The antihypertensive pharmaceutical composition ~~of~~ according to claim 7, wherein the ~~amount of Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof~~ content of the calcium channel blocker is in the range of 5 to 15 mg.

[Claim 11] The antihypertensive pharmaceutical composition ~~of~~ according to claim 10, wherein the ~~amount of Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof~~ content of the calcium channel blocker is in the range of 5 to 10 mg.

[Claim 12] The antihypertensive pharmaceutical composition ~~of~~ according to claim 1, wherein the pharmaceutical composition is an oral dosage form.

[Claim 13] The antihypertensive pharmaceutical composition ~~of~~ according to claim 12, wherein the dosage form is a single tablet.

~~[Claim 14] Use of: Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an angiotensin II receptor blocker; and Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as a calcium channel blocker, for the preparation of a medicament for alleviation or treatment of hypertension, heart failure, coronary heart disease, ischemic heart disease, ischemic peripheral vascular disease, hypertensive renal failure, cerebral apoplexy or arteriosclerosis in a mammal.~~

~~[Claim 15] Use of: Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an angiotensin II receptor blocker; and Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as a calcium channel blocker,for the preparation of an antihypertensive pharmaceutical composition for treating a hypertension in a mammal.~~

~~[Claim 16] The use of claim 15, wherein the mammal is human.~~

~~[Claim 17] The use of claim 15, wherein a pharmaceutically acceptable salt of Fimasartan is a Fimasartan potassium salt, hydrochloride, calcium salt, sulfate, adipate, camsylate or besylate.~~

~~[Claim 18] The use of claim 17, wherein a pharmaceutically acceptable salt of Fimasartan is a Fimasartan potassium salt.~~

~~[Claim 19] The use of claim 15, wherein a pharmaceutically acceptable salt of Amlodipine is an Amlodipine besylate.~~

~~[Claim 20] The use of claim 15, wherein the amount of Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof comprised in the composition is in the range of 0.5 to 240 mg, and the amount of Amlodipine, an siomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof is in the range of 0.1 to 20 mg.~~

[Claim 14] A pharmaceutical composition for the prevention, alleviation or treatment of hypertension, heart failure, coronary heart disease, ischemic heart disease, ischemic peripheral vascular disease, hypertensive renal failure, cerebral apoplexy or arteriosclerosis, comprising Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an angiotensin II receptor blocker; and Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as a calcium channel blocker.